



10/533,502 (RCE)

***** Welcome to STN International *****
 ***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:26:23 ON 10 JAN 2007

=> file reg

=> Uploading C:\Program Files\Stnexp\Queries\rce10533502.str



chain nodes :

14 16 17 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 18 19 20 21 22

chain bonds :

7-21 14-16 14-23 16-17 19-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21 21-22

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-21 8-9 9-10 14-16 14-23 16-17 18-19 18-22 19-20 19-23 20-21 21-22

isolated ring systems :

containing 1 :

G1:C,N

G2:C,S

G3:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom

Generic attributes :

17:


Type of Ring System : Polycyclic

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 0 SEA SSS SAM L1

=> s l1 full

L3 1 SEA SSS FUL L1

=> dis

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 790685-52-8 REGISTRY


ED Entered STN: 30 Nov 2004

CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[3-[4-(6-methoxy-1,5-naphthyridin-4-yl)-1H-1,2,3-triazol-1-yl]propyl]-3-oxo- (9CI) (CA INDEX NAME)

MF C22 H21 N7 O4 S2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

L4 1 L3

=> dis bib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:965373 CAPLUS Full-text

DN 141:388634

TI Quinoline and naphthyridine antibacterial agents

IN Axten, Jeffrey Michael; Miller, William Henry; Seefeld, Mark Antony

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096982	A2	20041111	WO 2003-US35201	20031104
	WO 2004096982	A3	20050217		
	W:	AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003303956	A1	20041123	AU 2003-303956	20031104
	EP 1560821	A2	20050810	EP 2003-816120	20031104
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006510729	T	20060330	JP 2004-571466	20031104
	US 2006166977	A1	20060727	US 2005-533502	20050502
PRAI	US 2002-423858P	P	20021105		
	WO 2003-US35201	W	20031104		

OS MARPAT 141:388634

AB Quinoline and naphthyridine derivs. useful in the treatment of bacterial infections in mammals, particularly humans, are described. Preparation of 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid [3-[4-(6-methoxy-[1,5]naphthyridin-4-yl)-[1,2,3]triazol-1-yl]propyl]amide is exemplified.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.30	177.56

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-0.78

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:27:33 ON 10 JAN 2007